Harald Schmidt holds dual degrees in Medicine and Pharmacy and is a leading figure in network and systems medicine. His work focuses on redefining disease classification by shifting from symptom- and organ-based definitions to mechanism-based approaches, leveraging big data, network pharmacology, and multi-target drug validation for diagnostic-guided repurposing of existing drugs.
He has applied these strategies to address unmet medical needs, progressing from computational models to clinical validation. He previously coordinated the H2020 REPO-TRIAL project and currently leads the REPO4EU sister initiative establishing a European platform and infrastructure for systems medicine and precision drug repurposing.
With a career spanning academia (Germany, USA, Australia, Netherlands), industry (Abbott Labs), and biotech (Vasopharm), Harald holds multiple drug and diagnostic patents and has contributed to spin-offs and licensing deals. He is also active in science communication as a podcaster and author, including the book The End of Medicine As We Know It.
